PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers

PD-L1 expression and tumor mutational burden (TMB) have emerged as important biomarkers of response to immune checkpoint inhibitor (ICI) therapy. These biomarkers have each succeeded and failed in predicting responders for different cancer types. We sought to describe the PD-L1 expression landscape...

Full description

Bibliographic Details

Published in:	JCI insight Vol. 4; no. 6
Main Authors:	Yarchoan, Mark, Albacker, Lee A., Hopkins, Alexander C., Montesion, Meagan, Murugesan, Karthikeyan, Vithayathil, Teena T., Zaidi, Neeha, Azad, Nilofer S., Laheru, Daniel A., Frampton, Garrett M., Jaffee, Elizabeth M.
Format:	Journal Article
Language:	English
Published:	United States American Society for Clinical Investigation 21.03.2019
Subjects:	Clinical Medicine Genetics Immunology Immunotherapy Cancer
ISSN:	2379-3708, 2379-3708
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!